Gender differences in C-reactive protein, interleukin-1 receptor antagonist and adiponectin levels in the metabolic syndrome: A population-based study

Diabetic Medicine

Volumn 25, Issue 6, 2008, Pages 747-750

  Saltevo, J ^a   Vanhala, M ^b   Kautiainen, H ^c   Kumpusalo, E ^d,e   Laakso, M ^d  

^a Central Hospital of Middle Finland   (Finland)

^b Laukaa Health Centre   (Finland)

^c Medcare Foundation   (Finland)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Adiponectin; C reactive protein; Gender difference; Interleukin 1 receptor antagonist; Metabolic syndrome

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH CARE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; SEX DIFFERENCE;

ADIPONECTIN; ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DIABETIC ANGIOPATHIES; FEMALE; FINLAND; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; RISK FACTORS; SEX FACTORS;

EID: 44649193809     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2008.02440.x     Document Type: Article

References (29)

1. Expert panel on detection, evaluation, treatment of high blood cholesterol in adults (Adult Treatment Panel III). Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA 2001 285 : 2486 2497.
2. Albert KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet 2005 366 : 1059 1062.
3. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001 86 : 1930 1935.
4. Matsuzawa Y. Adipocytokines and metabolic syndrome. Semin Vasc Med 2005 5 : 34 39.
5. Rathmann W, Haastert B, Herder C, Hauner H, Koenig W, Meisinger C et al. Differential association of adiponectin with cardiovascular risk markers in men and women? The KORA survey 2000. Int J Obes (Lond) 2007 31 : 770 776.
6. Snijder MB, Heine RJ, Seidell JC, Bouter LM, Stehouwer CDA, Nijpels G et al. Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women. The Hoorn Study. Diabetes Care 2006 29 : 2498 2503.
7. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998 41 : 1241 1248.
8. Laaksonen DE, Niskanen L, Nyyssönen K, Punnonen K, Tuomainen TP, Salonen JT. C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study. Eur Heart J 2005 26 : 1783 1789.
9. Laaksonen DE, Niskanen L, Nyyssönen K, Punnonen K, Tuomainen T-P, Valkonen V-P et al. C-reactive protein and development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004 47 : 1403 1410.
10. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001 286 : 327 334.
11. Snijder MB, Dekker JM, Visser M, Stehouwer CDA, Yudkin JS, Bouter LM et al. Prospective relation of C-reactive protein in type 2 diabetes (letter). Diabetes Care 2003 26 : 1656 1657.
12. Doi Y, Kiyohara Y, Kubo M, Ninomiya T, Wakugawa Y, Yonemoto K et al. Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care 2005 28 : 2497 2500.
13. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean MEJ, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002 51 : 2016 2021.
14. Thorand B, Baumert J, Kolb H, Meisinger C, Chambless L, Koenig W et al. Sex differences in the prediction of type 2 diabetes by inflammatory markers. Results from MONICA/KORA Augsburg case-cohort study, 1984-2002. Diabetes Care 2007 30 : 854 860.
15. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999 340 : 448 454.
16. Salmenniemi U, Ruotsalainen E, Pihlajamäki J, Vauhkonen I, Kainulainen S, Punnonen K et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation 2004 110 : 3842 3848.
17. Dinarello CA. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 2000 343 : 732 734.
18. Ruotsalainen E, Salmenniemi U, Vauhkonen I, Pihlajamäki J, Punnonen K, Kainulainen S et al. Changes in inflammatory cytokines are related to impaired glucose tolerance in offspring of type 2 diabetic subjects. Diabetes Care 2006 29 : 2714 2720.
19. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977 33 : 412 419.
20. Thorand B, Baumert J, Döring A, Herder C, Kolb H, Rathmann W et al. Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis 2006 184 : 216 224.
21. Lakoski SG, Cushman M, Criqui M, Rundek T, Blumenthal RS, D'Agostino RB Jr et al. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J 2006 152 : 593 598.
22. Després JP. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk. Eur Heart J 2006 8 (Suppl. B B4 B12.
23. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes and the metabolic syndrome. J Clin Invest 2006 116 : 1784 1792.
24. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006 29 : 1357 1362.
25. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes. A systematic review and meta-analysis. JAMA 2006 295 : 1288 1299.
26. Crandall C, Palla S, Reboussin B, Hu P, Barrett-Connor E, Reuben D et al. Cross-sectional association between markers of inflammation and serum sex steroid levels in postmenopausal estrogen/progestin interventions trial. J Womens Health 2006 15 : 14 23.
27. Gregg EW, Gu Q, Cheng YJ, Narayan KMV, Cowie CC. Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med 2007 147 : 149 155.
28. Haffner SM, Miettinen H, Stern MP. Relatively more atherogenic coronary heart disease risk factors in prediabetic women than prediabetic men. Diabetologia 1997 40 : 711 717.
29. Pischon T, Hu FB, Rexrode KM, Girman CJ, Manson JE, Rimm EB. Inflammation, the metabolic syndrome, and risk of coronary heart disease in women and men. Atherosclerosis 2008 197 : 392 399.